Literature DB >> 3102563

Sodium valproate: its use in primary psychiatric disorders.

S L McElroy, P E Keck, H G Pope.   

Abstract

Sodium valproate has been reported to be effective in the treatment of recurrent major affective and schizoaffective disorders. The records of 36 consecutive patients with various psychiatric diagnoses, who received valproate at our center, were retrospectively reviewed. None of these patients displayed a diagnosable neurologic disorder or paroxysmal EEG activity. Sixteen (44%) of the 36 patients experienced a moderate to marked response to valproate. The diagnoses of bipolar or schizoaffective disorder and the presence of nonparoxysmal EEG abnormalities both predicted a favorable response. The authors conclude that valproate deserves further study as a possible treatment for major affective disorder.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102563

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

Review 1.  Drug alternatives to lithium in manic-depressive disorders.

Authors:  D M Shaw
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 3.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 4.  The ability of lithium and other mood stabilizers to decrease suicide risk and prevent relapse.

Authors:  C L Bowden
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 5.  Role of antiepileptic drugs in the management of eating disorders.

Authors:  Susan L McElroy; Anna I Guerdjikova; Brian Martens; Paul E Keck; Harrison G Pope; James I Hudson
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

Review 6.  The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate.

Authors:  S C Dilsaver; A C Swann; A M Shoaib; T C Bowers
Journal:  J Psychiatry Neurosci       Date:  1993-03       Impact factor: 6.186

7.  Valproate in Bipolar Disorder: Case Examples From a Family Practice.

Authors:  J Sloan Manning
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

8.  Alopecia and mood stabilizers: two case reports.

Authors:  C Uehlinger; L Barrelet; M Touabi; P Baumann
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.